People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.
DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.
Exosomes were used for hair loss treatment, showing results 33 days after the second session. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.
Hair loss theory suggests imbalance between Vitamin D Receptor (VDR) and Androgen Receptor (AR) activation. Proposed treatment includes upregulating VDR, downregulating AR, and improving mitochondrial health.
Treatment options for female alopecia androgenetica, discussing the availability of spironolactone online in The Netherlands and other potential treatments like finasteride, minoxidil and RU58841.
Aminexil is similar to Minoxidil but less effective and not widely used, with some users reporting minor regrowth. It is not FDA-approved and has been removed from some products, though some people still use it, often in combination with Minoxidil.
The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.
A user experienced mild side effects from 0.5mg finasteride daily, including increased estradiol and minor gynecomastia. They are considering taking a low dose of exemestane to reduce estrogen levels.
The user is concerned about having a straight, low hairline after a hair transplant and is unable to take finasteride due to high estrogen and prolactin levels. They have used minoxidil with limited success and are considering further transplants to lower the hairline, while others suggest the risks of using up donor hair too quickly.
Clascoterone is suggested as an alternative for those who experience side effects from finasteride and dutasteride. It is not widely available yet, but some users are obtaining it from compounding pharmacies or suppliers like Echemi.
A user experienced accelerated hairline recession after adding dutasteride to their regimen of topical finasteride and minoxidil, despite reduced hair shedding. They were informed that ELISA testing for DHT levels can be highly inaccurate.
A 30-year-old is seeking advice on hair loss treatment, currently using oral minoxidil, finasteride, mesotherapy, and a supplement. They are experiencing shedding and are anxious about the effectiveness of the treatment, asking if they should continue or consider other options like topicals or microneedling.
The conversation is about whether stopping Redensyl, unlike Minoxidil, allows you to maintain hair growth benefits. The user is considering Redensyl as an alternative to Minoxidil due to concerns about hair loss upon cessation of Minoxidil.
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.
Hair loss sufferers becoming hyper aware of shedding, and the various treatments available for reducing shedding. The conversation also discussed differentiating between shedding and balding, as well as the potential side effects from using certain treatments.
The user has been using minoxidil for almost 6 months and finasteride for almost 4 months, experiencing significant shedding and minimal stabilization. They are considering switching to dutasteride if no improvements are seen and are advised to be patient, as results may take up to 2 years.
Annual hair shedding occurs for user, lasting 3 months, despite various factors. User takes Finasteride, Minoxidil, and Dutasteride, and experiences regrowth but fears weakening hairline.
Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.
Dutasteride mesotherapy in women with metabolic syndrome accelerated hair loss after initial regrowth, while women without metabolic syndrome saw continuous regrowth. The user with mild insulin resistance is hesitant to try topical dutasteride and seeks experiences from others with insulin resistance.
The conversation is about finding a source for sterile dutasteride for mesotherapy to avoid side effects from oral 5AR blockers. The user is currently using microneedling and 0.01% topical dutasteride and plans to use transplants.
The conversation discusses hair regrowth treatments, including stem cell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.
Verteporfin is discussed as a potential treatment for hair regrowth, but skepticism exists about its effectiveness in regenerating extracted hair follicles. The conversation also mentions the possibility of needing a hair transplant by 2028.
A user is frustrated about early balding despite older male relatives retaining hair into old age. Another user plans to start finasteride soon to address their hair thinning.
TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
A user experienced increased pimples and cysts after two years on dutasteride, possibly due to hormonal changes. Suggestions included seeing an endocrinologist, using supplements like boron and DIM, adjusting diet, and reducing body fat to manage side effects.
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.
Finasteride's effectiveness and side effects may vary based on male phenotypes, with some users noting differences in response related to body and facial hair characteristics. Some users report success with lower doses, while others experience side effects, suggesting individual variability in response to the treatment.